IRCT20180204038608N1招募中2 期
Comparison of Fingolimod whit Interferon Therapy in Patients with Multiple Sclerosis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Age should be between 18 to 55 years old
- •The type of disease should be Relapsing Remitting
- •There should not be any evidence of relapse in the past 30 days
- •EDSS score should be between 0 to 5.5
排除标准
- •Have Relapse or use of Corticosteroids in the past 30 days
- •Have an active infection
- •Have a history of diabetes
- •Have cardiac problems and use of anti arrhythmic drugs
- •Taking drugs such as Azathioprine and Methotrexate
- •WBCs less than 3500 and lymphocyte count less than 800
- •Taking heart beat reducer drugs
研究者
相似试验
尚未招募
不适用
Study of absorption and elimination rate of Fingolimod 0.5-mg capsule in comparison with Fingolimod brand Capsule (Gilenya®).Bioequivalence study.IRCT20200407046981N26Zahravi pharmaceutical company24
招募中
不适用
Efficacy and safety of interferon-free treatment in patients with chronic hepatitis Cchronic hepatitis CJPRN-UMIN000037575Osaka university1,000
进行中（未招募）
3 期
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisMultiple SclerosisNCT01892722Novartis Pharmaceuticals240
已完成
不适用
comparison of Fingolimode and Betaferon(high dose) in M.S treatmentMultiple SclerosisIRCT2015112025146N1Isfahan University of Medical Sciences50
招募中
3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100